← Back to the library

Retatrutide

An investigational triple receptor agonist

Investigational human trials
Illustrative bottle labeled Retatrutide, investigational peptideILLUSTRATION · NOT A PRODUCT

An investigational medicine that acts on GIP, GLP-1, and glucagon receptors; it has not been approved for public use.

What it is

Retatrutide is a peptide-based triple receptor agonist being studied by Lilly in clinical trials for obesity, type 2 diabetes, and related conditions.

What the evidence says

Phase 3 trials have reported results, but retatrutide remains investigational. Clinical trial findings must be assessed with the full study data and regulatory review.

What remains uncertain

Its final benefit-risk profile and any approved indications are not established. Products claiming to be retatrutide outside clinical trials are not equivalent to the studied medicine.

Primary sources

This page is for education only. It is not medical advice, a treatment recommendation, or a guide to obtaining or using a peptide. Speak with a qualified clinician about personal health decisions.